Preferred Label : NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous Cytotoxic T Lymphocytes;
NCIt synonyms : Autologous NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Cytotoxic T Lymphocytes; NY-ESO-1/MAGE-A4/PRAME/Survivin/SSX2-specific Autologous CTLs;
NCIt definition : A preparation of autologous cytotoxic T-lymphocytes (CTL) that are specifically reactive
to five tumor-associated antigens (TAAs), cancer-testis antigen NY-ESO-1, melanoma-associated
antigen 4 (MAGE-A4), preferentially expressed antigen in melanoma (PRAME), survivin
and synovial sarcoma X breakpoint 2 (SSX2; cancer/testis antigen 5.2; CT5.2), with
potential antineoplastic activity. Autologous peripheral blood mononuclear cells (PBMCs)
are collected and exposed ex vivo to autologous dendritic cells (DCs) that are pulsed
with pepmixes, which contain overlapping peptide libraries (15 mers overlapping by
11 amino acids) spanning the entire sequence of each of the five target antigens,
and simultaneously treated with the Th1-polarizing and pro-proliferative cytokines
interleukin (IL) 6 (IL-6), IL-7, IL-12 and IL-15. The treated cells are expanded in
culture with IL-2 and IL-15. Upon administration of the NY-ESO-1/MAGE-A4/PRAME/survivin/SSX2-specific
autologous CTLs, these cells target tumor cells expressing these TAAs, which leads
to cell lysis and inhibition of cell proliferation. These five TAAs are upregulated
in a variety of tumor cells and play key roles in tumor cell proliferation and survival,
but are absent or minimally expressed on normal, healthy human cells.;
Origin ID : C118367;
UMLS CUI : C4724803;
Semantic type(s)
- Cell [UMLS semantic type]
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
